Metastat Inc (MTST) 0.3800 $MTST MetaStat Demon
Post# of 273242
Posted On: 05/18/2015 2:22:25 AM
Metastat Inc (MTST) 0.3800 $MTST
MetaStat Demonstrates MenaCalc Lung(TM) Is Prognostic for Outcome in Non-Small Cell Lung Cancer
Business Wire - Tue Apr 21, 12:00PM CDT
--Support Usefulness of MenaCalc(TM) as Prognostic Test for Predicting Outcome Beyond Early-Stage Breast Cancer to Include Squamous Cell Carcinoma of Lung
MetaStat CEO Oscar L. Bronsther, M.D. to Participate in Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa on April 17
Business Wire - Tue Apr 14, 6:30AM CDT
Oscar L. Bronsther, M.D., CEO of MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will participate in a panel discussion at the Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa, FL on Friday, April 17.
MetaStat Discussed in Medscape and Other News Outlets
Business Wire - Thu Apr 09, 6:30AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, was featured in Medscape.com, WNYM-AM, WHCR-FM and the Boston Business Journal.
MetaStat Appoints Martin J. Driscoll to Board of Directors
Business Wire - Tue Apr 07, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has appointed Martin J. Driscoll to its Board of Directors, effective immediately.
MetaStat Announces Closing of Series B Private Placement
Business Wire - Tue Mar 31, 4:43PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, announced today the final closing of its Series B Preferred Stock private placement (the "Offering"
resulting in total gross proceeds of $3.4 million. Institutional and accredited investors including certain members of the company's board of directors and management participated in the transaction. H.C. Wainwright & Co., LLC acted as lead placement agent. Alere Financial Partners, LLC, a division of Clancy Financial Services Inc. acted as co-placement agent.
MetaStat Enters into Agreement to Access Tumor Samples and Clinical Data from Kaiser Foundation Hospitals
Business Wire - Tue Jan 27, 7:56AM CST
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has executed a material/data transfer agreement with Kaiser Foundation Hospitals. Under the terms of the agreement, MetaStat will receive de-identified tissue samples, clinical data and medical histories for up to 500 patients with or without metastatic breast cancer for testing using the Company's MetaSite Breast(TM) and MenaCalc Breast(TM) diagnostic assays for the early and reliable prediction of systemic metastasis.
MetaStat Closes First Round of a $3.5 Million Private Placement
Business Wire - Tue Jan 06, 10:23AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has consummated an initial closing of $1.3 million in a private placement of up to $3.5 million of shares of its Series B Preferred Stock to institutional and accredited investors including certain members of the Company's Board of Directors.
MetaStat to Present at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 06, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will be a presenting company at the Biotech Showcase(TM) 2015 Conference to be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, CA.
ATS Labs Announces New Name and Introduces New CEO
PR Newswire - Mon Dec 08, 7:30AM CST
ATS Labs is happy to announce that it is changing its company name to Accuratus Lab Services. ATS Labs recently completed a large acquisition of the assets of Microtest Laboratories of Agawam, Massachusetts, enabling it to expand its service offering into the growing medical device and pharmaceutical market segments. Company Executive Chairman Tom Burnell said, "The new identity and logo had to satisfy all of the existing expectations and strengths associated with the historical ATS Labs and Microtest Laboratories businesses while simultaneously personifying the scientific experience, quality solutions and accurate test results the combined companies provide to the growing medical device, biopharmaceutical and antimicrobial industries." Accuratus is derived from the Latin word accurate.
MetaStat Completes Divestiture of Its Therapeutic Assets
Business Wire - Tue Dec 02, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has completed the divestiture of its therapeutic assets. As a result of this divestiture, MetaStat's sole focus is developing its MetaSite Breast(TM) and MenaCalc(TM) near-term product opportunities.
MetaStat Spotlighted in Three Publications
Business Wire - Mon Oct 27, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, was the subject of recent articles in Boston Magazine, Medical Device Daily and MedCity News.
MetaStat Appoints Richard J. Berman and H. Philip Goodeve to Board of Directors
Business Wire - Tue Oct 21, 7:55AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, appointed Richard J. Berman and H. Philip Goodeve to its Board of Directors, effective October 15. Mr. Berman and Mr. Goodeve replace Warren Lau and Dr. Patrick Mooney, both of whom have resigned from the Board. In addition, Johan M. (Thijs) Spoor has resigned as Chairman of the Board while remaining a Board member.
MetaStat's Diagnostic Technology Spotlighted in WABC-TV News Special on October 4
Business Wire - Wed Oct 08, 7:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, has its licensed technology spotlighted in a WABC-TV news special that aired on Saturday, October 4.
MetaStat to Present at 13th Annual BIO Investor Forum on October 8 in San Francisco
Business Wire - Mon Oct 06, 7:01AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the 13th Annual BIO Investor Forum on October 8, 2014 at 2:00 pm PDT in San Francisco. Dr. Bronsther will provide an update on the Company's business activities.
MetaStat to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11
Business Wire - Thu Sep 04, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11 at 3:30 PM PDT. Dr. Bronsther will be providing an overview of the Company and its business activities.
MetaStat to Present at Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Business Wire - Thu Aug 28, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw 16th Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 2:05 pm EDT. Dr. Bronsther will provide an update on the Company's business activities.
MetaStat, Inc. Announces Memorandum of Understanding to Transfer its Therapeutic Business
ACCESSWIRE - Thu Jul 17, 8:25AM CDT
MONTCLAIR, NJ. / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on July 14, 2014 it entered into a binding Memorandum of Understanding (MOU) to transfer its therapeutic assets to a newly formed private company, ASET Therapeutics. ASET will be led by David Epstein, former chief scientific officer of OSI Pharmaceuticals, who will remain as a director of MetaStat for at least 6 months following consummation of the transaction.
ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc.
PR Newswire - Mon Jul 14, 7:00AM CDT
Today, ATS Labs, Inc. (ATS), majority owned by Ampersand Capital Partners, announced that it acquired the assets of MicroTest Labs, Inc. (MTL) of Agawam, MA. The acquisition of MTL is the first step in the strategy of ATS to expand its microbiology and chemistry laboratory services platform to support the medical device and biopharmaceutical industries. The combined companies will soon be known as Accuratus Lab Services, a name that personifies the quality and accuracy of testing results and scientific solutions that support the antimicrobial, consumer product, medical device, and biopharmaceutical industries.
MetaStat, Inc. Closes Equity Financing
ACCESSWIRE - Wed Jul 02, 11:18AM CDT
MONTCLAIR, NJ / ACCESSWIRE / July 2, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on June 30, 2014, it entered into a securities purchase agreement in a private placement totaling $5.7 million, inclusive of the automatic exchange of outstanding convertible promissory notes in the aggregate principal amount of approximately $3.3 million.
MetaStat Demonstrates MenaCalc Lung(TM) Is Prognostic for Outcome in Non-Small Cell Lung Cancer
Business Wire - Tue Apr 21, 12:00PM CDT
--Support Usefulness of MenaCalc(TM) as Prognostic Test for Predicting Outcome Beyond Early-Stage Breast Cancer to Include Squamous Cell Carcinoma of Lung
MetaStat CEO Oscar L. Bronsther, M.D. to Participate in Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa on April 17
Business Wire - Tue Apr 14, 6:30AM CDT
Oscar L. Bronsther, M.D., CEO of MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will participate in a panel discussion at the Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa, FL on Friday, April 17.
MetaStat Discussed in Medscape and Other News Outlets
Business Wire - Thu Apr 09, 6:30AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, was featured in Medscape.com, WNYM-AM, WHCR-FM and the Boston Business Journal.
MetaStat Appoints Martin J. Driscoll to Board of Directors
Business Wire - Tue Apr 07, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has appointed Martin J. Driscoll to its Board of Directors, effective immediately.
MetaStat Announces Closing of Series B Private Placement
Business Wire - Tue Mar 31, 4:43PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, announced today the final closing of its Series B Preferred Stock private placement (the "Offering"
resulting in total gross proceeds of $3.4 million. Institutional and accredited investors including certain members of the company's board of directors and management participated in the transaction. H.C. Wainwright & Co., LLC acted as lead placement agent. Alere Financial Partners, LLC, a division of Clancy Financial Services Inc. acted as co-placement agent. MetaStat Enters into Agreement to Access Tumor Samples and Clinical Data from Kaiser Foundation Hospitals
Business Wire - Tue Jan 27, 7:56AM CST
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has executed a material/data transfer agreement with Kaiser Foundation Hospitals. Under the terms of the agreement, MetaStat will receive de-identified tissue samples, clinical data and medical histories for up to 500 patients with or without metastatic breast cancer for testing using the Company's MetaSite Breast(TM) and MenaCalc Breast(TM) diagnostic assays for the early and reliable prediction of systemic metastasis.
MetaStat Closes First Round of a $3.5 Million Private Placement
Business Wire - Tue Jan 06, 10:23AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has consummated an initial closing of $1.3 million in a private placement of up to $3.5 million of shares of its Series B Preferred Stock to institutional and accredited investors including certain members of the Company's Board of Directors.
MetaStat to Present at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 06, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will be a presenting company at the Biotech Showcase(TM) 2015 Conference to be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, CA.
ATS Labs Announces New Name and Introduces New CEO
PR Newswire - Mon Dec 08, 7:30AM CST
ATS Labs is happy to announce that it is changing its company name to Accuratus Lab Services. ATS Labs recently completed a large acquisition of the assets of Microtest Laboratories of Agawam, Massachusetts, enabling it to expand its service offering into the growing medical device and pharmaceutical market segments. Company Executive Chairman Tom Burnell said, "The new identity and logo had to satisfy all of the existing expectations and strengths associated with the historical ATS Labs and Microtest Laboratories businesses while simultaneously personifying the scientific experience, quality solutions and accurate test results the combined companies provide to the growing medical device, biopharmaceutical and antimicrobial industries." Accuratus is derived from the Latin word accurate.
MetaStat Completes Divestiture of Its Therapeutic Assets
Business Wire - Tue Dec 02, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has completed the divestiture of its therapeutic assets. As a result of this divestiture, MetaStat's sole focus is developing its MetaSite Breast(TM) and MenaCalc(TM) near-term product opportunities.
MetaStat Spotlighted in Three Publications
Business Wire - Mon Oct 27, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, was the subject of recent articles in Boston Magazine, Medical Device Daily and MedCity News.
MetaStat Appoints Richard J. Berman and H. Philip Goodeve to Board of Directors
Business Wire - Tue Oct 21, 7:55AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, appointed Richard J. Berman and H. Philip Goodeve to its Board of Directors, effective October 15. Mr. Berman and Mr. Goodeve replace Warren Lau and Dr. Patrick Mooney, both of whom have resigned from the Board. In addition, Johan M. (Thijs) Spoor has resigned as Chairman of the Board while remaining a Board member.
MetaStat's Diagnostic Technology Spotlighted in WABC-TV News Special on October 4
Business Wire - Wed Oct 08, 7:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, has its licensed technology spotlighted in a WABC-TV news special that aired on Saturday, October 4.
MetaStat to Present at 13th Annual BIO Investor Forum on October 8 in San Francisco
Business Wire - Mon Oct 06, 7:01AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the 13th Annual BIO Investor Forum on October 8, 2014 at 2:00 pm PDT in San Francisco. Dr. Bronsther will provide an update on the Company's business activities.
MetaStat to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11
Business Wire - Thu Sep 04, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Aegis Capital Corp. 2014 Healthcare & Technology Conference on September 11 at 3:30 PM PDT. Dr. Bronsther will be providing an overview of the Company and its business activities.
MetaStat to Present at Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Business Wire - Thu Aug 28, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw 16th Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 10, 2014 at 2:05 pm EDT. Dr. Bronsther will provide an update on the Company's business activities.
MetaStat, Inc. Announces Memorandum of Understanding to Transfer its Therapeutic Business
ACCESSWIRE - Thu Jul 17, 8:25AM CDT
MONTCLAIR, NJ. / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on July 14, 2014 it entered into a binding Memorandum of Understanding (MOU) to transfer its therapeutic assets to a newly formed private company, ASET Therapeutics. ASET will be led by David Epstein, former chief scientific officer of OSI Pharmaceuticals, who will remain as a director of MetaStat for at least 6 months following consummation of the transaction.
ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc.
PR Newswire - Mon Jul 14, 7:00AM CDT
Today, ATS Labs, Inc. (ATS), majority owned by Ampersand Capital Partners, announced that it acquired the assets of MicroTest Labs, Inc. (MTL) of Agawam, MA. The acquisition of MTL is the first step in the strategy of ATS to expand its microbiology and chemistry laboratory services platform to support the medical device and biopharmaceutical industries. The combined companies will soon be known as Accuratus Lab Services, a name that personifies the quality and accuracy of testing results and scientific solutions that support the antimicrobial, consumer product, medical device, and biopharmaceutical industries.
MetaStat, Inc. Closes Equity Financing
ACCESSWIRE - Wed Jul 02, 11:18AM CDT
MONTCLAIR, NJ / ACCESSWIRE / July 2, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that on June 30, 2014, it entered into a securities purchase agreement in a private placement totaling $5.7 million, inclusive of the automatic exchange of outstanding convertible promissory notes in the aggregate principal amount of approximately $3.3 million.
(0)
(0)Scroll down for more posts ▼